
M. D. I. Uddin
Examiner (ID: 14773)
| Most Active Art Unit | 2169 |
| Art Unit(s) | 2169 |
| Total Applications | 819 |
| Issued Applications | 615 |
| Pending Applications | 73 |
| Abandoned Applications | 146 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 10491226
[patent_doc_number] => 20150376246
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-12-31
[patent_title] => 'HIGH AFFINITY DIGOXIGENIN BINDING PROTEINS'
[patent_app_type] => utility
[patent_app_number] => 14/766259
[patent_app_country] => US
[patent_app_date] => 2014-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 41
[patent_figures_cnt] => 41
[patent_no_of_words] => 30434
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14766259
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/766259 | High affinity digoxigenin binding proteins | Mar 12, 2014 | Issued |
Array
(
[id] => 14057871
[patent_doc_number] => 10233219
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-03-19
[patent_title] => Methods and systems for designing and/or characterizing soluble lipidated ligand agents
[patent_app_type] => utility
[patent_app_number] => 14/783489
[patent_app_country] => US
[patent_app_date] => 2014-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 42661
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14783489
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/783489 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | Mar 12, 2014 | Issued |
Array
(
[id] => 10670874
[patent_doc_number] => 20160017019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-01-21
[patent_title] => 'USE OF PLANT CELLS EXPRESSING A TNFalpha POLYPEPTIDE INHIBITOR IN THERAPY'
[patent_app_type] => utility
[patent_app_number] => 14/773349
[patent_app_country] => US
[patent_app_date] => 2014-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 26850
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14773349
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/773349 | Use of plant cells expressing a TNFalpha polypeptide inhibitor in therapy | Mar 5, 2014 | Issued |
Array
(
[id] => 9568639
[patent_doc_number] => 20140186353
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-07-03
[patent_title] => 'Treatment Of Inflammatory Diseases By Inhibiting Cold-Inducible RNA-Binding Protein (CIRP)'
[patent_app_type] => utility
[patent_app_number] => 14/196354
[patent_app_country] => US
[patent_app_date] => 2014-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 10118
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14196354
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/196354 | Treatment of inflammatory diseases by inhibiting cold-inducible RNA-binding protein (CIRP) | Mar 3, 2014 | Issued |
Array
(
[id] => 9719736
[patent_doc_number] => 20140255435
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-09-11
[patent_title] => 'Vaccine'
[patent_app_type] => utility
[patent_app_number] => 14/196511
[patent_app_country] => US
[patent_app_date] => 2014-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 10626
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14196511
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/196511 | Vaccine | Mar 3, 2014 | Abandoned |
Array
(
[id] => 11915423
[patent_doc_number] => 09783600
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-10-10
[patent_title] => 'Apolipoprotein C3 (ApoCIII) antagonists and methods of their use to remove ApoCIII inhibition of lipoprotein lipase (LPL)'
[patent_app_type] => utility
[patent_app_number] => 14/770395
[patent_app_country] => US
[patent_app_date] => 2014-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 13183
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14770395
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/770395 | Apolipoprotein C3 (ApoCIII) antagonists and methods of their use to remove ApoCIII inhibition of lipoprotein lipase (LPL) | Feb 24, 2014 | Issued |
Array
(
[id] => 14005587
[patent_doc_number] => 10221230
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-03-05
[patent_title] => HER-1, HER-3 and IGF-1R compositions and uses thereof
[patent_app_type] => utility
[patent_app_number] => 14/770335
[patent_app_country] => US
[patent_app_date] => 2014-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 40
[patent_figures_cnt] => 98
[patent_no_of_words] => 19243
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14770335
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/770335 | HER-1, HER-3 and IGF-1R compositions and uses thereof | Feb 24, 2014 | Issued |
Array
(
[id] => 10656201
[patent_doc_number] => 20160002345
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-01-07
[patent_title] => 'A COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA'
[patent_app_type] => utility
[patent_app_number] => 14/769158
[patent_app_country] => US
[patent_app_date] => 2014-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 27718
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14769158
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/769158 | A COMPOUND THAT SPECIFICALLY BINDS TO KIR3DL2 FOR USE IN THE TREATMENT OF PERIPHERAL T CELL LYMPHOMA | Feb 19, 2014 | Abandoned |
Array
(
[id] => 9656285
[patent_doc_number] => 20140227290
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-08-14
[patent_title] => 'METHOD FOR INCREASING N-GLYCOSYLATION SITE OCCUPANCY ON THERAPEUTIC GLYCOPROTEINS PRODUCED IN PICHIA PASTORIS'
[patent_app_type] => utility
[patent_app_number] => 14/181786
[patent_app_country] => US
[patent_app_date] => 2014-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 45
[patent_figures_cnt] => 45
[patent_no_of_words] => 40188
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14181786
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/181786 | METHOD FOR INCREASING N-GLYCOSYLATION SITE OCCUPANCY ON THERAPEUTIC GLYCOPROTEINS PRODUCED IN PICHIA PASTORIS | Feb 16, 2014 | Abandoned |
Array
(
[id] => 9538298
[patent_doc_number] => 20140162946
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-06-12
[patent_title] => 'FORMULATIONS AND METHODS FOR WEIGHT LOSS AND BODY CONTOURING'
[patent_app_type] => utility
[patent_app_number] => 14/179937
[patent_app_country] => US
[patent_app_date] => 2014-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2829
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14179937
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/179937 | Formulations and methods for weight loss and body contouring | Feb 12, 2014 | Issued |
Array
(
[id] => 11922701
[patent_doc_number] => 09790271
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-10-17
[patent_title] => 'Methods for increasing immunoglobulin A levels'
[patent_app_type] => utility
[patent_app_number] => 14/765162
[patent_app_country] => US
[patent_app_date] => 2014-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 7
[patent_no_of_words] => 24672
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 146
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14765162
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/765162 | Methods for increasing immunoglobulin A levels | Jan 30, 2014 | Issued |
Array
(
[id] => 9490608
[patent_doc_number] => 20140141014
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-05-22
[patent_title] => 'ANTIBODIES THAT INHIBIT METALLOPROTEINS'
[patent_app_type] => utility
[patent_app_number] => 14/168024
[patent_app_country] => US
[patent_app_date] => 2014-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 22868
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14168024
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/168024 | Antibodies that inhibit metalloproteins | Jan 29, 2014 | Issued |
Array
(
[id] => 9603500
[patent_doc_number] => 20140200180
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-07-17
[patent_title] => 'METHOD FOR PRODUCING PROTEINS IN PICHIA PASTORIS THAT LACK DETECTABLE CROSS BINDING ACTIVITY TO ANTIBODIES AGAINST HOST CELL ANTIGENS'
[patent_app_type] => utility
[patent_app_number] => 14/155878
[patent_app_country] => US
[patent_app_date] => 2014-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 54
[patent_figures_cnt] => 54
[patent_no_of_words] => 36022
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14155878
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/155878 | METHOD FOR PRODUCING PROTEINS IN PICHIA PASTORIS THAT LACK DETECTABLE CROSS BINDING ACTIVITY TO ANTIBODIES AGAINST HOST CELL ANTIGENS | Jan 14, 2014 | Abandoned |
Array
(
[id] => 10761975
[patent_doc_number] => 20160108128
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-04-21
[patent_title] => 'ANTIBODIES THAT BIND TO JAGGED 1'
[patent_app_type] => utility
[patent_app_number] => 14/761062
[patent_app_country] => US
[patent_app_date] => 2014-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 26170
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14761062
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/761062 | Antibodies that bind to Jagged 1 | Jan 14, 2014 | Issued |
Array
(
[id] => 9462748
[patent_doc_number] => 20140127175
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-05-08
[patent_title] => 'GLUCAGON ANALOGUES'
[patent_app_type] => utility
[patent_app_number] => 14/149669
[patent_app_country] => US
[patent_app_date] => 2014-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 10403
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14149669
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/149669 | GLUCAGON ANALOGUES | Jan 6, 2014 | Abandoned |
Array
(
[id] => 9462747
[patent_doc_number] => 20140127174
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-05-08
[patent_title] => 'GLUCAGON ANALOGUES'
[patent_app_type] => utility
[patent_app_number] => 14/149640
[patent_app_country] => US
[patent_app_date] => 2014-01-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 11034
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14149640
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/149640 | GLUCAGON ANALOGUES | Jan 6, 2014 | Abandoned |
Array
(
[id] => 10176062
[patent_doc_number] => 09206256
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-12-08
[patent_title] => 'DDR1-binding agents and methods of use thereof'
[patent_app_type] => utility
[patent_app_number] => 14/148669
[patent_app_country] => US
[patent_app_date] => 2014-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 30008
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14148669
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/148669 | DDR1-binding agents and methods of use thereof | Jan 5, 2014 | Issued |
Array
(
[id] => 11799653
[patent_doc_number] => 09540444
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-01-10
[patent_title] => 'Neutralizing antibodies and methods of use thereof'
[patent_app_type] => utility
[patent_app_number] => 14/144650
[patent_app_country] => US
[patent_app_date] => 2013-12-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 90
[patent_no_of_words] => 31599
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 146
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14144650
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/144650 | Neutralizing antibodies and methods of use thereof | Dec 30, 2013 | Issued |
Array
(
[id] => 11463869
[patent_doc_number] => 09580488
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-02-28
[patent_title] => 'Fusion tags and expression vector system for the expression of human parathyroid hormone (rhPTH)'
[patent_app_type] => utility
[patent_app_number] => 14/653897
[patent_app_country] => US
[patent_app_date] => 2013-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 10
[patent_no_of_words] => 6105
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 119
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14653897
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/653897 | Fusion tags and expression vector system for the expression of human parathyroid hormone (rhPTH) | Dec 22, 2013 | Issued |
Array
(
[id] => 10911753
[patent_doc_number] => 20140314769
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-10-23
[patent_title] => 'Neutralizing Antibodies And Methods Of Use Thereof'
[patent_app_type] => utility
[patent_app_number] => 14/109082
[patent_app_country] => US
[patent_app_date] => 2013-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 48
[patent_figures_cnt] => 48
[patent_no_of_words] => 48773
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14109082
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/109082 | Neutralizing antibodies and methods of use thereof | Dec 16, 2013 | Issued |